ElevateBio adds another $ 525 million to its war chest, as it plans to build the state-of-the-art manufacturing base camp – Endpoints News
Eli Lilly’s research division has generated considerable fervor for its first-line reading of Phase II of its next generation of Alzheimer’s drugs, donanemab. But after releasing the da…
